Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals, which are in the process of merging, updated their commercial activities.
Jaguar is launching a national TV advertising campaign this month for Neonorm Foal and a radio campaign in key dairy markets for Neonorm Calf., its lead non-prescription products.
“The integrated, multichannel marketing initiatives Jaguar has launched over the past four months in support of Neonorm Foal and Neonorm Calf are all aligned with our Neonorm commercial strategy of connecting directly with dairy farmers, vets, horse owners and other members of the equine community, in a targeted and engaging way, to help build the Neonorm brand and drive sales, both directly and through our core dairy market distributor, ANIMART, and our exclusive distributor for Neonorm Foal, Henry Schein,” Lisa Conte, president and CEO of Jaguar, said in a statement.
In addition, Napo has signed an agreement with Alamo Pharma Services to establish and manage a national sales team for Mytesi. The launch of the sales force took place this week. The sales representatives have begun reaching out to doctors who have large populations of HIV patients and are high-volume prescribers of antiretroviral therapies.
Mytesi, launched by Napo in October 2016, is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
An abstract based on new crofelemer (Mytesi) data from a supplemental analysis of the Napo-sponsored ADVENT trial has been accepted for presentation as a poster exhibition at the 9th IAS Conference on HIV Science in Paris on July 23-26.